RecruitingNCT06717178

Cancer and Aging Research Group (CARG) Chemotherapy Toxicity Risk Scores in Older Adults With Cancer in China

Correlation of the Cancer and Aging Research Group (CARG) Chemotherapy Toxicity Risk Scores and Unplanned Hospitalizations in Older Cancer Patients--A Multi-center Prospective Cohort Study


Sponsor

RenJi Hospital

Enrollment

322 participants

Start Date

Dec 24, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of this observational study is to learn about the impact of chemotherapy-related toxicity on older cancer patients in China. The main question it aims to answer is: Does the Cancer and Aging Research Group (CARG) chemotherapy toxicity risk score predict chemotherapy-related toxicity in Chinese cancer patients over age 70? Participants over age 70 on systemic chemotherapy will answer questions listed in the CARG chemotherapy toxicity risk tool.


Eligibility

Min Age: 70 Years

Inclusion Criteria6

  • Age≥ 70 years old
  • Confirmed diagnosis of solid tumor (any stage)
  • ECOG-PS score 0-2 points
  • Admission to the hospital for a new chemotherapy regimen (initial or change)
  • Patients need to have the ability to read and write, or communicate in Chinese
  • The patient must have the ability to give informed consent.

Exclusion Criteria4

  • Patients who are on immunotherapy and/or targeted therapy only
  • Patients with hematologic malignancy
  • Patients with severe infections (sepsis, severe respiratory tract infections, severe urinary tract infections, severe abdominal infections, etc.).
  • Patients with severe heart, liver, and kidney dysfunction or failure

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGChemotherapy

Admission to the hospital for a new chemotherapy regimen (initial or change)


Locations(2)

Henan Cancer Hospital

Zhengzhou, Henan, China

Renji Hospital

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06717178


Related Trials